December 10, 2018 07:43 AM EST
R&D

0-for-2: An­oth­er fad­ed drug star in Ax­o­van­t's much-hyped pipeline falls, tar­nish­ing Ra­maswamy's deal-mak­ing rep

John Carroll

Editor & Founder

A few years ago, when Vivek Ra­maswamy bagged nelotanserin for his pre­mier biotech start­up Ax­o­vant in a small-mon­ey deal with Are­na, the ex-hedge fund play­er …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

FDA vac­cine chief Pe­ter Marks pledges to stay as long as he's wel­come

Am­gen names Stan­ford ge­neti­cist and biotech founder to CSO post

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times